IP Library Granted Patent US 7,816,380
Granted Patent B2
US 7,816,380 · App. 11/920,306 · Granted Oct 19, 2010

1-hydroxycycloalkanecarboxamide derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,816,380
App. No.
11/920,306
Granted
Oct 19, 2010
Kind
B2
Abstract

α-Hydroxycycloalkanecarboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, wherein formula (a) is a single or double bond; R 1 , R 2 and R 3 are each independently selected from H, halogen and OH; or R 1 and R 2 attached to the same carbon atom together represent oxo; R 4 is H or methyl; R 5 is Cl or I 2 ; R 6 is selected from —CO 2 —C 1-4 alkyl, —O—C 1-4 alkyl, —O—C 1-4 haloalkyl, 2-methyltetrazol-5-yl, 5-methyl-1,2,4-oxadiazol-3-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 5-halomethyl-1,2,4-oxadiazol-3-yl, 3-halomethyl-1,2,4-oxadiazol-5-yl, tetrazol-5-yl, 5-halomethyl-1,2,3-triazolyl, and 5-methyl-1,2,3-triazolyl; R 7 and R 8 are each independently Cl or I 2 ; and n is 0 or 1, are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

Claims (399)

1. A compound having the formula (I):

or a pharmaceutically acceptable salt thereof, wherein

is a single or double bond;

R 1 , R 2 , and R 3 are each independently selected from H, halogen and OH; or

R 1 and R 2 attached to the same carbon atom together represent oxo;

R 4 is H or methyl;

R 5 is Cl or F;

R 6 is selected from 2-methyltetrazol-5-yl, 5-methyl-1,2,4-oxadiazol-3-yl, 3-methy1,2,4-oxadiazol-5-yl, 5-halomethyl-1,2,4-oxadiazol-3-yl, 3-halomethyl-1,2,4-oxadiazol-5-yl, tetrazol-5-yl, 5-halomethyl-1,2,3-triazolyl, and 5-methyl-1,2,3-triazolyl;

R 7 and R 8 are each independently Cl or F; and

n is 0 or 1.

2. A compound of claim 1 wherein at least one of R 1 , R 2 , and R 3 is a fluorine atom.

3. A compound of claim 1 wherein n is 0.

4. A compound of claim 1 wherein n is 1.

5. A compound of claim 1 wherein R 6 is 2-methyl-tetrazol-5-yl.

6. pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7. A compound of claim 1 selected from the group consisting of:

R1/R2

R 4

R 6

R 5

R 7

R 8

H/H

H

2-CH 3 -2H-tetrazol-5-yl

F

F

Cl

H/H

Me

5-CH 2 F-1,2,4-oxadiazole

F

F

Cl

H/H

Me

3-CH 3 -1,2,4-oxadiazole

F

Cl

Cl

H/H

Me

3-CH 3 -1,2,4-oxadiazole

F

Cl

F

H/H

Me

2-CH 3 -2H-tetrazol-5-yl

F

F

Cl

H/H

Me

2-CH 3 -2H-tetrazol-5-yl

F

F

F

H/H

Me

5-CH 3 -1,2,4-oxadiazole

Cl

F

Cl

H/H

Me

5-CH 3 -1,2,4-oxadiazole

F

Cl

Cl

H/H

Me

3-CH 3 -1,2,4-oxadiazole

F

F

Cl

H/H

Me

2-CH 3 -2H-tetrazol-5-yl

Cl

Cl

Cl

H/H

Me

2-CH 3 -2H-tetrazol-5-yl

F

Cl

Cl

H/H

Me

2-CH 3 -2H-tetrazol-5-yl

F

Cl

F

H/H

H

3-CH 3 -1,2,4-oxadiazole

F

Cl

Cl

H/H

H

5-CH 3 -1,2,4-oxadiazole

F

F

Cl

H/H

Me

5-CH 3 -1,2,4-oxadiazole

F

F

F

H/H

H

2-CH 3 -2H-tetrazol-5-yl

F

Cl

Cl

H/H

H

2-CH 3 -2H-tetrazol-5-yl

Cl

F

Cl

H/H

Me

2-CH 3 -2H-tetrazol-5-yl

Cl

F

H

H/H

H

3-CH 3 -1,2,4-oxadiazole

F

F

Cl

H/H

H

2-CH 3 -2H-tetrazol-5-yl

Cl

Cl

Cl

H/H

Me

2-CH 3 -2H-tetrazol-5-yl

Cl

F

F

H/H

Me

5-CH 3 -1,2,4-oxadiazole

F

Cl

F

H/H

Me

3-CH 3 -1,2,4-oxadiazole

Cl

Cl

F

H/H

H

2-CH 3 -2H-tetrazol-5-yl

F

F

F

H/H

H

5-CH 3 -1,2,4-oxadiazole

F

Cl

Cl

H/H

H

2-CH 3 -2H-tetrazol-5-yl

Cl

F

F

H/H

H

2-CH 3 -2H-tetrazol-5-yl

Cl

Cl

F

H/H

H

2-CH 3 -2H-tetrazol-5-yl

F

Cl

F

H/H

H

3-CH 3 -1,2,4-oxadiazole

F

F

F

2-F/H

Me

2-CH 3 -2H-tetrazol-5-yl

F

F

Cl

2-F/H

H

2-CH 3 -2H-tetrazol-5-yl

F

F

Cl

3-F/3-F

Me

2-CH 3 -2H-tetrazol-5-yl

F

F

Cl

3-F/3-F

H

2-CH 3 -2H-tetrazol-5-yl

F

F

Cl

3-F/3-F

Me

2H-tetrazol-5-yl

F

F

Cl

3-F/3-F

H

3-CH 3 -1,2,4-oxadiazole

F

F

Cl

3-F/3-F

H

5-CH 3 -1,2,4-oxadiazole

F

F

Cl

3-F/3-F

H

3-CH 3 -1,2,4-oxadiazole

Cl

F

Cl

3-F/3-F

H

2-CH 3 -2H-tetrazol-5-yl

Cl

F

Cl

3-F/3-F

H

2-CH 3 -2H-tetrazol-5-yl

F

Cl

Cl

3-F/3-F

H

3-CH 3 -1,2,4-oxadiazole

Cl

F

Cl

3-F/3-F

H

5-CH 3 -1,2,4-oxadiazole

Cl

F

Cl

3-F/3-F

Me

5-CH 2 F-1,2,3-triazole

F

F

Cl

3-F/3-F

H

2-CH 3 -2H-tetrazol-5-yl

Cl

Cl

Cl

3-OH/H

Me

2-CH 3 -2H-tetrazol-5-yl

F

F

Cl

oxo

Me

2-CH 3 -2H-tetrazol-5-yl

F

F

Cl

3-F/H

Me

2-CH 3 -2H-tetrazol-5-yl

F

F

Cl

2-OH/H

H

2-CH 3 -2H-tetrazol-5-yl

F

F

Cl

R1/R2

R 4

R 6

R 5

R 7

R 8

4-F/4-F

Me

2-CH 3 -2H-tetrazol-5-yl

F

F

Cl

4-F/4-F

H

2-CH 3 -2H-tetrazol-5-yl

F

F

Cl

4-F/4-F

H

2H-tetrazol-5-yl

F

F

Cl

4-F/4-F

Me

5-CH 3 -1,2,3-triazole

F

F

Cl

4-F/4-F

H

2-CH 3 -2H-tetrazol-5-yl

Cl

F

Cl

4-F/4-F

H

2-CH 3 -2H-tetrazol-5-yl

F

Cl

Cl

4-F/4-F

H

2-CH 3 -2H-tetrazol-5-yl

Cl

F

Cl

4-F/4-F

Me

5-CH 3 -1,2,4-oxadiazole

Cl

F

Cl

4-F/4-F

H

2-CH 3 -2H-tetrazol-5-yl

F

Cl

Cl

4-F/4-F

Me

5-CH 2 F-1,2,3-triazole

F

F

Cl

4-F/4-F

Me

5-CH 2 F-1,2,4-oxadiazole

F

F

Cl

4-F/4-F

H

2-CH 3 -2H-tetrazol-5-yl

Cl

Cl

Cl

4-F/4-F

H

2-CH 2 CHF 2 -2H-tetrazol-

F

F

Cl

5-yl

4-F/4-F

H

2-CHF 2 -2H-tetrazol-5-yl

F

F

Cl

N-((1R)-1-{5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoropyridin-2-yl}ethyl)-4,4-difluoro-1-hydroxycyclohexanecarboxamide;

N-({5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoropyridin-2-yl}methyl)-4,4-difluoro-1-hydroxycyclohexanecarboxamide; and

N-((1R)-1-{5-[5-chloro-3-fluoro-2-(2-methyl-2H tetrazol-5-yl)phenyl]-3-fluoropyridin-2-yl}ethyl)-4,4-difluoro-1,2-dihydroxycyclohexanecarboxamide;

or a pharmaceutically acceptable salt thereof.

Assignments (4)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
CHANGE OF NAME Recorded Jan 26, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023845/0940 →